These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 18619726

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells.
    Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Götz M, Döhner H, Bunjes D, Schmitt M.
    Br J Haematol; 2009 Jan; 144(2):195-205. PubMed ID: 19016717
    [Abstract] [Full Text] [Related]

  • 4. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.
    Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD.
    Exp Hematol; 2009 Feb; 37(2):256-65. PubMed ID: 19056158
    [Abstract] [Full Text] [Related]

  • 5. Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.
    Uchiyama T, Sato N, Narita M, Yamahira A, Iwabuchi M, Furukawa T, Sone H, Takahashi M.
    Hematol Oncol; 2013 Sep; 31(3):156-63. PubMed ID: 23108877
    [Abstract] [Full Text] [Related]

  • 6. The receptor for hyaluronic acid-mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation.
    Chen J, Schmitt A, Bunjes D, Chen B, Schmitt M.
    Int J Oncol; 2007 May; 30(5):1119-27. PubMed ID: 17390013
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Profound inhibition of antigen-specific T-cell effector functions by dasatinib.
    Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, Zezula J, Greiner E, Gostick E, Price DA, Einsele H, Seggewiss R.
    Clin Cancer Res; 2008 Apr 15; 14(8):2484-91. PubMed ID: 18413841
    [Abstract] [Full Text] [Related]

  • 10. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
    Schmitt M, Li L, Giannopoulos K, Chen J, Brunner C, Barth T, Schmitt A, Wiesneth M, Döhner K, Döhner H, Greiner J.
    Exp Hematol; 2006 Dec 15; 34(12):1709-19. PubMed ID: 17157168
    [Abstract] [Full Text] [Related]

  • 11. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.
    Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, Böhm A, Herndlhofer S, Tschachler E, Superti-Furga G, Jäger U, Valent P.
    Eur J Clin Invest; 2009 Dec 15; 39(12):1098-109. PubMed ID: 19744184
    [Abstract] [Full Text] [Related]

  • 12. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.
    Seggewiss R, Loré K, Greiner E, Magnusson MK, Price DA, Douek DC, Dunbar CE, Wiestner A.
    Blood; 2005 Mar 15; 105(6):2473-9. PubMed ID: 15572591
    [Abstract] [Full Text] [Related]

  • 13. Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A.
    Blake SJ, Hughes TP, Lyons AB.
    Exp Hematol; 2012 Aug 15; 40(8):612-21.e6. PubMed ID: 22521768
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3.
    Nerreter T, Köchel C, Jesper D, Eichelbrönner I, Putz E, Einsele H, Seggewiss-Bernhardt R.
    Exp Hematol; 2014 Sep 15; 42(9):773-82.e1-3. PubMed ID: 24882272
    [Abstract] [Full Text] [Related]

  • 16. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
    Johnson FM, Saigal B, Talpaz M, Donato NJ.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):6924-32. PubMed ID: 16203784
    [Abstract] [Full Text] [Related]

  • 19. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.
    Baumgartner C, Gleixner KV, Peter B, Ferenc V, Gruze A, Remsing Rix LL, Bennett KL, Samorapoompichit P, Lee FY, Pickl WF, Esterbauer H, Sillaber C, Superti-Furga G, Valent P.
    Exp Hematol; 2008 Oct 01; 36(10):1244-53. PubMed ID: 18619723
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.